{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:36:39Z","timestamp":1776789399144,"version":"3.51.2"},"publisher-location":"Cham","reference-count":155,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030404635","type":"print"},{"value":"9783030404642","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/10_2019_119","type":"book-chapter","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T01:02:24Z","timestamp":1576544544000},"page":"23-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Insights on the Formulation of Recombinant Proteins"],"prefix":"10.1007","author":[{"given":"Rita","family":"Ribeiro","sequence":"first","affiliation":[]},{"given":"Teresa Raquel","family":"Abreu","sequence":"additional","affiliation":[]},{"given":"Ana Catarina","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"119_CR1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1126\/science.1219021","volume":"338","author":"KA Dill","year":"2012","unstructured":"Dill KA, Maccallum JL (2012) The protein-folding problem, 50 years on. Science 338:1042\u20131047","journal-title":"Science"},{"key":"119_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/nature02261","volume":"426","author":"CM Dobson","year":"2003","unstructured":"Dobson CM (2003) Protein folding and misfolding. Nature 426:884\u2013890","journal-title":"Nature"},{"key":"119_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/antib2030452","volume":"89","author":"S Goswami","year":"2013","unstructured":"Goswami S, Wang W, Arakawa T, Ohtake S (2013) Developments and challenges for mAb-based therapeutics. Antibodies 89:452\u2013500","journal-title":"Antibodies"},{"key":"119_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.copbio.2019.01.014","volume":"60","author":"ME Krause","year":"2019","unstructured":"Krause ME, Sahin E (2019) Chemical and physical instabilities in manufacturing and storage of therapeutic proteins. Curr Opin Biotechnol 60:159\u2013167","journal-title":"Curr Opin Biotechnol"},{"key":"119_CR5","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/aic.11252","volume":"53","author":"TW Randolph","year":"2007","unstructured":"Randolph TW, Carpenter JF (2007) Engineering challenges of protein formulations. Am Inst Chem Eng J 53:1902\u20131907","journal-title":"Am Inst Chem Eng J"},{"key":"119_CR6","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/jps.22054","volume":"99","author":"DS Pisal","year":"2009","unstructured":"Pisal DS, Kosloski MP, Balu-iyer SV (2009) Delivery of therapeutic proteins. J Pharm Sci 99:2557\u20132575","journal-title":"J Pharm Sci"},{"key":"119_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","volume":"27","author":"MC Manning","year":"2010","unstructured":"Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27:544\u2013575","journal-title":"Pharm Res"},{"key":"119_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/pro.2659","volume":"24","author":"AJ Soulby","year":"2015","unstructured":"Soulby AJ, Heal JW, Barrow MP, Roemer RA, Connor PBO (2015) Does deamidation cause protein unfolding? A top-down tandem mass spectrometry study. Protein Sci 24:850\u2013860","journal-title":"Protein Sci"},{"key":"119_CR9","doi-asserted-by":"crossref","first-page":"22549","DOI":"10.1016\/S0021-9258(18)54607-X","volume":"266","author":"R Tyler-cross","year":"1991","unstructured":"Tyler-cross R, Schirchs V (1991) Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem 266:22549\u201322556","journal-title":"J Biol Chem"},{"key":"119_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0030295","volume":"7","author":"K Diepold","year":"2012","unstructured":"Diepold K et al (2012) Simultaneous assessment of asp isomerization and asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One 7:1\u201311","journal-title":"PLoS One"},{"key":"119_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jctb.4850","volume":"91","author":"D Gervais","year":"2016","unstructured":"Gervais D (2016) Protein deamidation in biopharmaceutical manufacture: understanding, control and impact. J Chem Technol Biotechnol 91:569\u2013575","journal-title":"J Chem Technol Biotechnol"},{"key":"119_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1461-5347(00)00248-0","volume":"3","author":"DA Parkins","year":"2000","unstructured":"Parkins DA, Lashmar UT (2000) The formulation of biopharmaceutical products. Pharm Sci Technol Today 3:129\u2013137","journal-title":"Pharm Sci Technol Today"},{"key":"119_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0891-5849(90)90006-5","volume":"9","author":"ER Stadtman","year":"1990","unstructured":"Stadtman ER (1990) Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9:315\u2013325","journal-title":"Free Radic Biol Med"},{"key":"119_CR14","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/jps.10216","volume":"91","author":"E Ha","year":"2002","unstructured":"Ha E, Wang WEI, Wang YJ (2002) Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 91:2252\u20132264","journal-title":"J Pharm Sci"},{"key":"119_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11095-013-1199-9","volume":"31","author":"R Torosantucci","year":"2014","unstructured":"Torosantucci R, Sch\u00f6neich C, Jiskoot W (2014) Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res 31:541\u2013553","journal-title":"Pharm Res"},{"key":"119_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/bit.260480511","volume":"48","author":"S Li","year":"1995","unstructured":"Li S, Schoneich C, Borchardt RT (1995) Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48:490\u2013500","journal-title":"Biotechnol Bioeng"},{"key":"119_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jps.20727","volume":"96","author":"WEI Wang","year":"2006","unstructured":"Wang WEI et al (2006) Antibody structure, instability, and formulation. J Pharm Sci 96:1\u201326","journal-title":"J Pharm Sci"},{"key":"119_CR18","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1002\/jps.21328","volume":"97","author":"S Kiese","year":"2008","unstructured":"Kiese S, Papppenberger A, Friess W, Mahler H (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347\u20134366","journal-title":"J Pharm Sci"},{"key":"119_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","volume":"185","author":"W Wang","year":"1999","unstructured":"Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129\u2013188","journal-title":"Int J Pharm"},{"key":"119_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0076-6879(99)09018-7","volume":"309","author":"BJF Carpenter","year":"1999","unstructured":"Carpenter BJF, Kendrick BS, Chang BS, Manning MC, Randolph TW (1999) Inhibition of stressed-induced aggregation of protein therapeutics. Methods Enzymol 309:236\u2013255","journal-title":"Methods Enzymol"},{"key":"119_CR21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/jps.21110","volume":"97","author":"LA Kueltzo","year":"2008","unstructured":"Kueltzo LA, Wang WEI, Randolph TW, Carpenter JF (2008) Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze\u2013thawing. J Pharm Sci 97:1801\u20131812","journal-title":"J Pharm Sci"},{"key":"119_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.cryobiol.2009.07.005","volume":"60","author":"CL Dias","year":"2010","unstructured":"Dias CL et al (2010) The hydrophobic effect and its role in cold denaturation. Cryobiology 60:91\u201399","journal-title":"Cryobiology"},{"key":"119_CR23","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1023\/A:1025771421906","volume":"20","author":"EY Chi","year":"2003","unstructured":"Chi EY, Krishnan S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20:1325\u20131336","journal-title":"Pharm Res"},{"key":"119_CR24","doi-asserted-by":"publisher","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","volume":"287","author":"MK Joubert","year":"2012","unstructured":"Joubert MK et al (2012) Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287:25266\u201325279","journal-title":"J Biol Chem"},{"key":"119_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/pro.309","volume":"19","author":"CB Andersen","year":"2010","unstructured":"Andersen CB, Manno M, Rischel C, Th\u00f3r\u00f3lfsson M, Martorana V (2010) Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci 19:279\u2013290","journal-title":"Protein Sci"},{"key":"119_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrd1695","volume":"4","author":"S Frokjaer","year":"2005","unstructured":"Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4:298\u2013306","journal-title":"Nat Rev Drug Discov"},{"key":"119_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nature01891","volume":"424","author":"F Chiti","year":"2003","unstructured":"Chiti F, Stefani M, Ramponi G, Dobson CM (2003) Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424:805\u2013808","journal-title":"Nature"},{"key":"119_CR28","doi-asserted-by":"publisher","first-page":"8397","DOI":"10.1021\/bi0105983","volume":"40","author":"L Nielsen","year":"2001","unstructured":"Nielsen L, Frokjaer S, Brange J, Uversky VN, Fink AL (2001) Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 40:8397\u20138409","journal-title":"Biochemistry"},{"key":"119_CR29","first-page":"5081","volume":"100","author":"NJ Agrawal","year":"2011","unstructured":"Agrawal NJ et al (2011) Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm 100:5081\u20135095","journal-title":"J Pharm"},{"key":"119_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/19420862.2015.1007828","volume":"7","author":"O Obrezanova","year":"2015","unstructured":"Obrezanova O et al (2015) Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs 7:352\u2013363","journal-title":"MAbs"},{"key":"119_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics10040165","volume":"10","author":"A Pandya","year":"2018","unstructured":"Pandya A, Howard MJ, Zloh M, Dalby PA (2018) An evaluation of the potential of NMR spectroscopy and computational modelling methods to inform biopharmaceutical formulations. Pharmaceutics 10:1\u201324","journal-title":"Pharmaceutics"},{"key":"119_CR32","unstructured":"ICH (1999) ICH Q6B \u2013 specifications: test procedures and acceptance criteria for biotechnological\/biological products. 1\u201316"},{"key":"119_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1021\/ac3032355","volume":"85","author":"A Beck","year":"2013","unstructured":"Beck A, Wagner-rousset E, Ayoub D, van Dorsselaer A, Sanglier-cianf\u00e9rani S (2013) Characterization of therapeutic antibodies and related products. Anal Chem 85:715\u2013736","journal-title":"Anal Chem"},{"key":"119_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4614-6486-0_4","volume-title":"Pharmaceutical biotechnology","author":"D Crommelin","year":"2013","unstructured":"Crommelin D (2013) Formulation of biotech products, including biopharmaceutical considerations. In: Pharmaceutical biotechnology. CRC Press, Boca Raton, pp 69\u201396"},{"key":"119_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4155\/tde.14.98","volume":"6","author":"U Angkawinitwong","year":"2015","unstructured":"Angkawinitwong U, Sharma G, Khaw PT, Brocchini S (2015) Solid-state protein formulations. Ther Deliv 6:59\u201382","journal-title":"Ther Deliv"},{"key":"119_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/jps.21504","volume":"98","author":"RJ Sol\u00e1","year":"2010","unstructured":"Sol\u00e1 RJ, Griebenow KAI (2010) Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 98:1223\u20131245","journal-title":"J Pharm Sci"},{"key":"119_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1517\/17425240903199143","volume":"6","author":"L Jorgensen","year":"2009","unstructured":"Jorgensen L, Hostrup S, Moeller EH, Grohganz H (2009) Recent trends in stabilising peptides and proteins in pharmaceutical formulation \u2013 considerations in the choice of excipients. Expert Opin Drug Deliv 6:1219\u20131230","journal-title":"Expert Opin Drug Deliv"},{"key":"119_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejps.2016.05.020","volume":"95","author":"B Peters","year":"2016","unstructured":"Peters B et al (2016) Effects of cooling rate in microscale and pilot scale freeze-drying \u2013 variations in excipient polymorphs and protein secondary structure. Eur J Pharm Sci 95:72\u201381","journal-title":"Eur J Pharm Sci"},{"key":"119_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2018.07.011","volume":"131","author":"V Gervasi","year":"2018","unstructured":"Gervasi V et al (2018) Parenteral protein formulations: an overview of approved products within the European Union. Eur J Pharm Biopharm 131:8\u201324","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR40","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","volume":"119","author":"P Garidel","year":"2017","unstructured":"Garidel P, Kuhn AB, Sch\u00e4fer LV, Karow-zwick AR, Blech M (2017) High-concentration protein formulations: how high is high. Eur J Pharm Biopharm 119:353\u2013360","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/10837450701247350","volume":"12","author":"A Hawe","year":"2007","unstructured":"Hawe A, Frie\u00df W (2007) Formulation development for hydrophobic therapeutic proteins. Pharm Dev Technol 12:223\u2013237","journal-title":"Pharm Dev Technol"},{"key":"119_CR42","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1016\/j.bbagen.2017.09.002","volume":"1861","author":"G Tedeschi","year":"2017","unstructured":"Tedeschi G, Mangiagalli M, Chmielewska S, Natalello A, Brocca S (2017) Aggregation properties of a disordered protein are tunable by pH and depend on its net charge per residue. Biochim Biophys Acta 1861:2543\u20132550","journal-title":"Biochim Biophys Acta"},{"key":"119_CR43","unstructured":"Hopkins E, Sharma S (2019) Physiology, acid base balance. StatPearls. http:\/\/europepmc.org\/books\/NBK507807 . Accessed 12 Oct 2019"},{"key":"119_CR44","first-page":"1","volume":"106","author":"D Roethlisberger","year":"2016","unstructured":"Roethlisberger D, Mahler H, Altenburger U, Pappenberger A (2016) If euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms? J Pharm Sci 106:1\u201311","journal-title":"J Pharm Sci"},{"key":"119_CR45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/biot.201400531","volume":"10","author":"S Bahrenburg","year":"2015","unstructured":"Bahrenburg S, Karow AR, Garidel P (2015) Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications. Biotechnol J 10:610\u2013622","journal-title":"Biotechnol J"},{"key":"119_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","volume":"20","author":"SJ Shire","year":"2009","unstructured":"Shire SJ (2009) Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708\u2013714","journal-title":"Curr Opin Biotechnol"},{"key":"119_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00726-007-0506-3","volume":"33","author":"T Arakawa","year":"2007","unstructured":"Arakawa T, Tsumoto K, Kita Y, Chang B, Ejima D (2007) Biotechnology applications of amino acids in protein purification and formulations. Amino Acids 33:587\u2013605","journal-title":"Amino Acids"},{"key":"119_CR48","doi-asserted-by":"publisher","first-page":"11831","DOI":"10.1021\/jp204462t","volume":"115","author":"D Shukla","year":"2011","unstructured":"Shukla D, Trout BL (2011) Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility. J Phys Chem 115:11831\u201311839","journal-title":"J Phys Chem"},{"key":"119_CR49","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jps.23427","volume":"102","author":"A Al-hussein","year":"2013","unstructured":"Al-hussein A, Gieseler H (2013) Investigation of histidine stabilizing effects on LDH during freeze-drying. J Pharm Sci 102:813\u2013826","journal-title":"J Pharm Sci"},{"key":"119_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(00)00423-3","volume":"203","author":"W Wang","year":"2000","unstructured":"Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203:1\u201360","journal-title":"Int J Pharm"},{"key":"119_CR51","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1015834724528","volume":"8","author":"MJ Pikal","year":"1991","unstructured":"Pikal MJ, Dellerman KM, Roy ML, Riggin RM (1991) The effects of formulation variables on the stability of freeze-dried human growth hormone. Pharm Res 8:427\u2013436","journal-title":"Pharm Res"},{"key":"119_CR52","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/jps.10154","volume":"91","author":"MJ Akers","year":"2002","unstructured":"Akers MJ (2002) Excipient-drug interactions in parenteral formulations. J Pharm Sci 91:2283\u20132300","journal-title":"J Pharm Sci"},{"key":"119_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejpb.2015.09.016","volume":"97","author":"TA Khan","year":"2015","unstructured":"Khan TA, Mahler H, Kishore RSK (2015) Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm 97:60\u201367","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR54","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1002\/jps.22129","volume":"99","author":"MK Goyal","year":"2010","unstructured":"Goyal MK, Roy I, Amin A, Banerjee UC, Bansal AK (2010) Stabilization of lysozyme by benzyl alcohol: surface tension and thermodynamic parameters. J Pharm Sci 99:4149\u20134161","journal-title":"J Pharm Sci"},{"key":"119_CR55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/jps.23362","volume":"102","author":"RL Hutchings","year":"2013","unstructured":"Hutchings RL, Singh SM, Cabello-Villegas J, Mallela KMG (2013) Effect of antimicrobial preservatives on partial protein unfolding and aggregation. J Pharm Sci 102:365\u2013376","journal-title":"J Pharm Sci"},{"key":"119_CR56","first-page":"1","volume":"26","author":"RL Bis","year":"2014","unstructured":"Bis RL, Singh SM, Cabello-villegas J, Mallela KMG (2014) Role of benzyl alcohol in the unfolding and aggregation of interferon alpha-2a. J Pharm Sci 26:1\u20139","journal-title":"J Pharm Sci"},{"key":"119_CR57","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1007\/s11095-015-1697-z","volume":"32","author":"P Heljo","year":"2015","unstructured":"Heljo P, Ross A, Zarraga IE, Pappenberger A, Mahler H-C (2015) Interactions between peptide and preservatives: effects on peptide self-interactions and antimicrobial efficiency in aqueous multi-dose formulations. Pharm Res 32:3201\u20133212","journal-title":"Pharm Res"},{"key":"119_CR58","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1517\/17425247.2013.780023","volume":"10","author":"J Jezek","year":"2013","unstructured":"Jezek J et al (2013) Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin Drug Deliv 10:811\u2013828","journal-title":"Expert Opin Drug Deliv"},{"key":"119_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0167-4838(96)00180-X","volume":"1337","author":"T Kocha","year":"1996","unstructured":"Kocha T, Yamaguchi M, Ohtaki H, Fukuda T, Aoyagi T (1996) Hydrogen peroxide-mediated degradation of protein: different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin. Biochim Biophys Acta 1337:319\u2013326","journal-title":"Biochim Biophys Acta"},{"key":"119_CR60","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.vaccine.2004.07.050","volume":"23","author":"GL Morefield","year":"2005","unstructured":"Morefield GL et al (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588\u20131595","journal-title":"Vaccine"},{"key":"119_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","volume":"22","author":"ML Mbow","year":"2010","unstructured":"Mbow ML, De Gregorio E, Valiante NM, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22:411\u2013416","journal-title":"Curr Opin Immunol"},{"key":"119_CR62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrmicro1681","volume":"5","author":"B Guy","year":"2007","unstructured":"Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505\u2013517","journal-title":"Nat Rev Microbiol"},{"key":"119_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/B978-0-12-804019-5.00005-0","volume-title":"Immunopotentiators in modern vaccines","author":"C Buonsanti","year":"2017","unstructured":"Buonsanti C, Oro UD (2017) Discovery of immune potentiators as vaccine adjuvants. In: Immunopotentiators in modern vaccines. Elsevier, Amsterdam, pp 85\u2013104"},{"key":"119_CR64","unstructured":"EMEA\/CPMP (2004) Guideline on adjuvants in vaccines. 1\u201318"},{"key":"119_CR65","doi-asserted-by":"publisher","first-page":"13406","DOI":"10.1074\/jbc.M500687200","volume":"280","author":"LS Jones","year":"2005","unstructured":"Jones LS et al (2005) Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 280:13406\u201313414","journal-title":"J Biol Chem"},{"key":"119_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2051013613480144","volume":"1","author":"CB Fox","year":"2013","unstructured":"Fox CB, Kramer RM, Lucien Barnes V, Dowling QM, Vedvick TS (2013) Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines Rev 1:7\u201320","journal-title":"Ther Adv Vaccines Rev"},{"key":"119_CR67","doi-asserted-by":"publisher","first-page":"S818","DOI":"10.1080\/21691401.2018.1513941","volume":"46","author":"M Kaurav","year":"2018","unstructured":"Kaurav M et al (2018) Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage. Artif Cells Nanomed Biotechnol 46:S818\u2013S831","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"119_CR68","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/03639045.2017.1278768","volume":"43","author":"C Yanan","year":"2017","unstructured":"Yanan C, Ping C, Binlong C, Suxin L, Hua G (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm 43:519\u2013530","journal-title":"Drug Dev Ind Pharm"},{"key":"119_CR69","unstructured":"EPAR \u2013 Product Information. European Medicines Agency. https:\/\/www.ema.europa.eu\/en . Accessed 13 Oct 2019"},{"key":"119_CR70","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","volume":"36","author":"G Walsh","year":"2018","unstructured":"Walsh G (2018) Biopharmaceutical benchmarks 2018. Nat Biotechnol 36:1136\u20131145","journal-title":"Nat Biotechnol"},{"key":"119_CR71","unstructured":"EMEA\/CHMP (2015) Guideline on similar biological medicinal products. pp 1\u20137"},{"key":"119_CR72","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF et al (2017) Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng 114:2696\u20132705","journal-title":"Biotechnol Bioeng"},{"key":"119_CR73","unstructured":"FDA (2015) Scientific considerations in demonstrating biosimilarity to a reference product. pp 1\u201324"},{"key":"119_CR74","unstructured":"EMEA\/CHMP (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. pp 1\u201313"},{"key":"119_CR75","first-page":"306","volume":"65","author":"M Kesik-brodacka","year":"2018","unstructured":"Kesik-brodacka M (2018) Progress in biopharmaceutical development. Int Union Biochem Mol Biol 65:306\u2013322","journal-title":"Int Union Biochem Mol Biol"},{"key":"119_CR76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5639\/gabij.2014.0304.039","volume":"3","author":"R Anour","year":"2014","unstructured":"Anour R (2014) Biosimilars versus \u2018biobetters\u2019 \u2013 a regulator\u2019s perspective. Generics Ans Biosimilars Initiat J 3:166\u2013167","journal-title":"Generics Ans Biosimilars Initiat J"},{"key":"119_CR77","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G et al (2012) Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869\u2013878","journal-title":"Lancet Oncol"},{"key":"119_CR78","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/bp070462h","volume":"24","author":"N Rathore","year":"2008","unstructured":"Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24:504\u2013514","journal-title":"Biotechnol Prog"},{"key":"119_CR79","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1021\/js980074x","volume":"87","author":"DR Shnek","year":"1998","unstructured":"Shnek DR, Hostettler DL, Bell MA, Olinger JM, Frank BH (1998) Physical stress testing of insulin suspensions and solutions. J Pharm Sci 87:1459\u20131465","journal-title":"J Pharm Sci"},{"key":"119_CR80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0939-6411(98)00004-6","volume":"45","author":"F Franks","year":"1998","unstructured":"Franks F (1998) Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm 45:221\u2013229","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR81","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.xphs.2017.03.014","volume":"106","author":"SM Patel","year":"2017","unstructured":"Patel SM et al (2017) Lyophilized drug product cake appearance: what is acceptable? J Pharm Sci 106:1706\u20131721","journal-title":"J Pharm Sci"},{"key":"119_CR82","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejpb.2017.01.024","volume":"114","author":"MA Mensink","year":"2017","unstructured":"Mensink MA, Frijlink HW, van der Voort K, Hinrichs WLJ (2017) How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions. Eur J Pharm Biopharm 114:288\u2013295","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR83","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejpb.2013.05.001","volume":"85","author":"W Cao","year":"2013","unstructured":"Cao W et al (2013) Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies. Eur J Pharm Biopharm 85:287\u2013293","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR84","unstructured":"FDA (1999) Container closure systems for packaging human drugs and biologics. pp 1\u201341"},{"key":"119_CR85","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1208\/s12249-018-1184-z","volume":"19","author":"M Wang","year":"2018","unstructured":"Wang M et al (2018) Interactions between biological products and product packaging and potential approaches to overcome them. AAPS PharmSciTech 19:3681\u20133686","journal-title":"AAPS PharmSciTech"},{"key":"119_CR86","first-page":"487","volume-title":"ICH quality guidelines: an implementation guide","author":"A Raghani","year":"2018","unstructured":"Raghani A, Li K, Bussiere JL, Bercu JP, Qiu J (2018) Process-related impurities in biopharmaceuticals. In: ICH quality guidelines: an implementation guide. Wiley, Hoboken, pp 487\u2013507"},{"key":"119_CR87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S1461-5347(99)00120-0","volume":"2","author":"B Dipaolo","year":"1999","unstructured":"Dipaolo B, Pennetti A, Nugent L, Venkat K, Venkat K (1999) Monitoring impurities in biopharmaceuticals produced by recombinant technology. Pharm Sci Technol Today 2:70\u201382","journal-title":"Pharm Sci Technol Today"},{"key":"119_CR88","first-page":"481","volume-title":"Physicochemical principles of pharmacy","author":"AT Florence","year":"2016","unstructured":"Florence AT, Attwood D (2016) Adverse events: the role of formulations and delivery systems. In: Physicochemical principles of pharmacy. Macmillan, Basingstoke, pp 481\u2013511"},{"key":"119_CR89","first-page":"1","volume":"87","author":"DP Elder","year":"2015","unstructured":"Elder DP, Kuentz M, Holm R (2015) Pharmaceutical excipients \u2013 quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci 87:1\u201312","journal-title":"Eur J Pharm Sci"},{"key":"119_CR90","unstructured":"WHO (2013) Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. pp 1\u201391"},{"key":"119_CR91","volume-title":"Good manufacturing practices for pharmaceuticals","author":"J Nally","year":"2007","unstructured":"Nally J (2007) Good manufacturing practices for pharmaceuticals. CRC Press, Boca Raton"},{"key":"119_CR92","unstructured":"EMEA\/CHMP (2007) Guideline on excipients in the dossier for application for marketing authorization of a medical product. pp 1\u201312"},{"key":"119_CR93","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","volume":"61","author":"WJ Pichler","year":"2006","unstructured":"Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61:912\u2013920","journal-title":"Allergy"},{"key":"119_CR94","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0149-2918(02)80075-3","volume":"24","author":"H Schellekens","year":"2002","unstructured":"Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720\u20131740","journal-title":"Clin Ther"},{"key":"119_CR95","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/2042098611406318","volume":"2","author":"MG Tovey","year":"2011","unstructured":"Tovey MG, Lallemand C (2011) Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2:113\u2013128","journal-title":"Ther Adv Drug Saf"},{"key":"119_CR96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00415-004-1202-9","volume":"251","author":"H Schellekens","year":"2004","unstructured":"Schellekens H, Casadevall N (2004) Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 251:4\u20139","journal-title":"J Neurol"},{"key":"119_CR97","first-page":"3241","volume":"98","author":"J Li","year":"2019","unstructured":"Li J et al (2019) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Am Soc Hematol 98:3241\u20133249","journal-title":"Am Soc Hematol"},{"key":"119_CR98","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.16.3.155","volume":"16","author":"G Schernthaner","year":"1993","unstructured":"Schernthaner G (1993) Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155\u2013165","journal-title":"Diabetes Care"},{"key":"119_CR99","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","volume":"36","author":"J Dumont","year":"2016","unstructured":"Dumont J, Euwart D, Mei B, Estes S, Kshirsagar R (2016) Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol 36:1110\u20131122","journal-title":"Crit Rev Biotechnol"},{"key":"119_CR100","first-page":"1473","volume":"7","author":"AS Robinson","year":"2012","unstructured":"Robinson AS (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol Bioeng 7:1473\u20131484","journal-title":"Biotechnol Bioeng"},{"key":"119_CR101","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","volume":"21","author":"S Hermeling","year":"2004","unstructured":"Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21:897\u2013903","journal-title":"Pharm Res"},{"key":"119_CR102","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/j.xphs.2018.06.029","volume":"107","author":"G Kijanka","year":"2018","unstructured":"Kijanka G et al (2018) Submicron size particles of a murine monoclonal antibody are more immunogenic than soluble oligomers or micron size particles upon subcutaneous administration in mice. J Pharm Sci 107:2847\u20132859","journal-title":"J Pharm Sci"},{"key":"119_CR103","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1208\/aapsj080359","volume":"8","author":"AS Rosenberg","year":"2006","unstructured":"Rosenberg AS (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8:501\u2013507","journal-title":"AAPS J"},{"key":"119_CR104","unstructured":"The United States Pharmacopeial Convention (2012) <788> Particulate matter in injections. pp 1\u20133"},{"key":"119_CR105","unstructured":"European Pharmacopoeia (2007) 2.9.19. Particulate contamination: sub-visible particles. pp 300\u2013302"},{"key":"119_CR106","unstructured":"European Pharmacopoeia (2007) 2.9.20. Particulate contamination: visible particles. p 302"},{"key":"119_CR107","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0006-291X(03)01466-9","volume":"308","author":"H Ito","year":"2003","unstructured":"Ito H, Nakashima T, So T, Hirata M, Inoue M (2003) Immunodominance of conformation-dependent B-cell epitopes of protein antigens. Biochem Biophys Res Commun 308:770\u2013776","journal-title":"Biochem Biophys Res Commun"},{"key":"119_CR108","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, Kolta A, Patrick M (2002) Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469\u2013475","journal-title":"N Engl J Med"},{"key":"119_CR109","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nbt1303","volume":"25","author":"G Shankar","year":"2007","unstructured":"Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555\u2013561","journal-title":"Nat Biotechnol"},{"key":"119_CR110","unstructured":"Groot, A. S. De, Mcmurry, J. & Moise, L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8, 1\u20137 (2008)"},{"key":"119_CR111","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G et al (2014) Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides \u2013 harmonized terminology and tactical recommendations. AAPS J 16:658\u2013673","journal-title":"AAPS J"},{"key":"119_CR112","unstructured":"EMEA\/CHMP (2007) Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. pp 1\u201318"},{"key":"119_CR113","unstructured":"EMEA\/CHMP (2012) Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. pp 1\u201310"},{"key":"119_CR114","unstructured":"FDA (2016) Assay development and validation for immunogenicity testing of therapeutic protein products. pp 1\u201331"},{"key":"119_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2018.09.049","volume":"552","author":"M Shah","year":"2018","unstructured":"Shah M (2018) New perspectives on protein aggregation during biopharmaceutical development. Int J Pharm 552:1\u20136","journal-title":"Int J Pharm"},{"key":"119_CR116","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","volume":"114","author":"LH Bookbinder","year":"2006","unstructured":"Bookbinder LH et al (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230\u2013241","journal-title":"J Control Release"},{"key":"119_CR117","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ejpb.2010.08.012","volume":"76","author":"L Schiefelbein","year":"2010","unstructured":"Schiefelbein L et al (2010) Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation. Eur J Pharm Biopharm 76:342\u2013350","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR118","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/bit.22983","volume":"108","author":"W Du","year":"2011","unstructured":"Du W, Klibanov AM (2011) Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol Bioeng 108:632\u2013636","journal-title":"Biotechnol Bioeng"},{"key":"119_CR119","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.addr.2011.08.003","volume":"63","author":"T Serno","year":"2011","unstructured":"Serno T, Geidobler R, Winter G (2011) Protein stabilization by cyclodextrins in the liquid and dried state. Adv Drug Deliv Rev 63:1086\u20131106","journal-title":"Adv Drug Deliv Rev"},{"key":"119_CR120","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/0192623307310945","volume":"36","author":"VJ Stella","year":"2008","unstructured":"Stella VJ, He Q (2008) Cyclodextrins. Toxicol Pathol 36:30\u201342","journal-title":"Toxicol Pathol"},{"key":"119_CR121","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijpharm.2018.05.048","volume":"546","author":"P Kozarewicz","year":"2018","unstructured":"Kozarewicz P, Loftsson T (2018) Novel excipients \u2013 regulatory challenges and perspectives \u2013 the EU insight. Int J Pharm 546:176\u2013179","journal-title":"Int J Pharm"},{"key":"119_CR122","unstructured":"FDA (2005) Nonclinical studies for the safety evaluation of pharmaceutical excipients. pp 1\u20139"},{"key":"119_CR123","first-page":"923","volume":"9","author":"L Zhu","year":"2015","unstructured":"Zhu L, Xu H (2015) The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Dove Press J 9:923\u2013942","journal-title":"Dove Press J"},{"key":"119_CR124","first-page":"1619","volume":"12","author":"F Fayad","year":"2018","unstructured":"Fayad F et al (2018) Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study. Dove Press J 12:1619\u20131625","journal-title":"Dove Press J"},{"key":"119_CR125","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v20.i23.30","volume":"20","author":"RI Mahato","year":"2003","unstructured":"Mahato RI, Narang AS, Th L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153\u2013214","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"119_CR126","unstructured":"Barnett AH, Bellary S (2007) Inhaled human insulin (Exubera\u00ae): clinical profile and patient considerations. Vasc Health Risk Manag 3:83\u201391"},{"key":"119_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Ii WHF (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:1\u20134","journal-title":"BMC Neurosci"},{"key":"119_CR128","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1080\/21691401.2018.1430695","volume":"46","author":"B Chaulagain","year":"2018","unstructured":"Chaulagain B, Jain A, Tiwari A, Verma A, Jain SK (2018) Passive delivery of protein drugs through transdermal route. Artif Cells Nanomed Biotechnol 46:S472\u2013S487","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"119_CR129","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.addr.2018.01.015","volume":"127","author":"Y Ye","year":"2018","unstructured":"Ye Y, Yu J, Wen D, Kahkoska AR, Gu Z (2018) Polymeric microneedles for transdermal protein delivery. Adv Drug Deliv Rev 127:106\u2013118","journal-title":"Adv Drug Deliv Rev"},{"key":"119_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/9783527632909","volume-title":"Pharmaceutical biotechnology drug discovery and clinical applications","author":"O Kayser","year":"2012","unstructured":"Kayser O, Warzecha H (2012) Pharmaceutical biotechnology drug discovery and clinical applications. Wiley-Blackwell, Hoboken"},{"key":"119_CR131","first-page":"113","volume":"66","author":"M Philippart","year":"2016","unstructured":"Philippart M et al (2016) Oral delivery of therapeutic proteins and peptides: an overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug Res 66:113\u2013120","journal-title":"Drug Res"},{"key":"119_CR132","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1517\/17425247.2015.961420","volume":"12","author":"R Vaishya","year":"2015","unstructured":"Vaishya R, Khurana V, Patel S, Mitra AK (2015) Long-term delivery of protein therapeutics. Expert Opin Drug Deliv 12:415\u2013440","journal-title":"Expert Opin Drug Deliv"},{"key":"119_CR133","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-030-00710-2_5","volume-title":"Pharmaceutical biotechnology","author":"DJA Crommelin","year":"2019","unstructured":"Crommelin DJA, Hawe A, Jiskoot W (2019) Formulation of biologics including biopharmaceutical considerations. In: Pharmaceutical biotechnology. Springer, Berlin, pp 83\u2013103"},{"key":"119_CR134","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4155\/tde-2019-0016","volume":"10","author":"C Ye","year":"2019","unstructured":"Ye C, Venkatraman S (2019) The long-term delivery of proteins and peptides using micro\/nanoparticles: overview and perspectives. Ther Deliv 10:10\u201313","journal-title":"Ther Deliv"},{"key":"119_CR135","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/cr200157d","volume":"112","author":"T Vermonden","year":"2012","unstructured":"Vermonden T, Censi R, Hennink WE (2012) Hydrogels for protein delivery. Chem Rev 112:2853\u20132888","journal-title":"Chem Rev"},{"key":"119_CR136","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ddtec.2009.03.003","volume":"5","author":"MAH Capelle","year":"2008","unstructured":"Capelle MAH, Arvinte T (2008) High-throughput formulation screening of therapeutic proteins. Drug Discov Today Technol 5:71\u201379","journal-title":"Drug Discov Today Technol"},{"key":"119_CR137","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1039\/B814377C","volume":"5","author":"GA Senisterra","year":"2009","unstructured":"Senisterra GA, Finerty PJ (2009) High throughput methods of assessing protein stability and aggregation. Mol Biosyst 5:217\u2013223","journal-title":"Mol Biosyst"},{"key":"119_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00037","volume":"9","author":"F Carbonell","year":"2018","unstructured":"Carbonell F, Iturria-Medina Y, Evans AC (2018) Mathematical modeling of protein misfolding mechanisms in neurological diseases: a historical overview. Front Neurol 9:1\u201316","journal-title":"Front Neurol"},{"key":"119_CR139","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1021\/jp070212j","volume":"111","author":"JM Andrews","year":"2007","unstructured":"Andrews JM, Roberts CJ (2007) A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1.aggregation with pre-equilibrated unfolding. J Phys Chem 111:7897\u20137913","journal-title":"J Phys Chem"},{"key":"119_CR140","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12033-007-9003-x","volume":"38","author":"NJ Mulder","year":"2008","unstructured":"Mulder NJ, Kersey P, Pruess M, Apweiler R (2008) In silico characterization of proteins: UniProt, InterPro and Integr8. Mol Biotechnol 38:165\u2013177","journal-title":"Mol Biotechnol"},{"key":"119_CR141","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1021\/jm8005977","volume":"51","author":"J Kirchmair","year":"2008","unstructured":"Kirchmair J et al (2008) The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J Med Chem 51:7021\u20137039","journal-title":"J Med Chem"},{"key":"119_CR142","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejpb.2015.10.016","volume":"98","author":"E Tamizi","year":"2016","unstructured":"Tamizi E, Jouyban A (2016) Forced degradation studies of biopharmaceuticals: Selection of stress conditions. Eur J Pharm Biopharm 98:26\u201346","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR143","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","volume":"9","author":"C Nowak","year":"2017","unstructured":"Nowak C et al (2017) Forced degradation of recombinant monoclonal antibodies: a practical guide. MAbs 9:1217\u20131230","journal-title":"MAbs"},{"key":"119_CR144","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/jps.22812","volume":"101","author":"A Hawe","year":"2012","unstructured":"Hawe A et al (2012) Forced degradation of therapeutic proteins. J Pharm Sci 101:895\u2013913","journal-title":"J Pharm Sci"},{"key":"119_CR145","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejpb.2006.09.009","volume":"65","author":"MAH Capelle","year":"2007","unstructured":"Capelle MAH, Gurny R, Arvinte T (2007) High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm 65:131\u2013148","journal-title":"Eur J Pharm Biopharm"},{"key":"119_CR146","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pro.5560070320","volume":"7","author":"A Ducret","year":"1998","unstructured":"Ducret A, Oostveen IVAN, Eng JK, In JRY, Aebersold R (1998) High throughput protein characterization by automated reverse-phase chromatography\/electrospray tandem mass spectrometry. Protein Sci 7:706\u2013719","journal-title":"Protein Sci"},{"key":"119_CR147","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/jps.22008","volume":"99","author":"HUI Zhao","year":"2010","unstructured":"Zhao HUI et al (2010) Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 99:2279\u20132294","journal-title":"J Pharm Sci"},{"key":"119_CR148","doi-asserted-by":"publisher","first-page":"118505","DOI":"10.1016\/j.ijpharm.2019.118505","volume":"568","author":"W Wang","year":"2019","unstructured":"Wang W, Ohtake S (2019) Science and art of protein formulation development. Int J Pharm 568:118505","journal-title":"Int J Pharm"},{"key":"119_CR149","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4939-2316-8_6","volume-title":"Quality by design for biopharmaceutical drug product development","author":"B Perez-ram\u00edrez","year":"2015","unstructured":"Perez-ram\u00edrez B, Guziewicz N, Simler R, Sreedhara A (2015) Approaches for early developability assessment of proteins to guide quality by design of liquid formulations. In: Quality by design for biopharmaceutical drug product development. Springer, Berlin, pp 87\u2013114"},{"key":"119_CR150","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/jps.24430","volume":"104","author":"A Jarasch","year":"2015","unstructured":"Jarasch A et al (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104:1885\u20131898","journal-title":"J Pharm Sci"},{"key":"119_CR151","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4155\/pbp.13.3","volume":"1","author":"J Zurdo","year":"2013","unstructured":"Zurdo J (2013) Developability assessment as an early de-risking tool for biopharmaceutical development. Pharm Bioprocess 1:29\u201350","journal-title":"Pharm Bioprocess"},{"key":"119_CR152","unstructured":"ICH (2009) ICH Q8(R2) \u2013 pharmaceutical development. pp 1\u201324"},{"key":"119_CR153","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10529-011-0822-2","volume":"34","author":"Y Grant","year":"2012","unstructured":"Grant Y, Matejtschuk P, Bird C, Wadhwa M, Dalby PA (2012) Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factor. Biotechnol Lett 34:641\u2013648","journal-title":"Biotechnol Lett"},{"key":"119_CR154","unstructured":"ICH (2005) ICH Q9 \u2013 quality risk management. pp 1\u201319"},{"key":"119_CR155","unstructured":"Moreton C (2009) Functionality and performance of excipients in a quality-by-design world. Am Pharm Rev:32\u201335"}],"container-title":["Advances in Biochemical Engineering\/Biotechnology","Current Applications of Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/10_2019_119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:13:13Z","timestamp":1613146393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/10_2019_119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030404635","9783030404642"],"references-count":155,"URL":"https:\/\/doi.org\/10.1007\/10_2019_119","relation":{},"ISSN":["0724-6145","1616-8542"],"issn-type":[{"value":"0724-6145","type":"print"},{"value":"1616-8542","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"17 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}